Results 181 to 190 of about 27,235 (300)

Functional analysis of bispecific antibody (EpCAMxCD3)‐mediated T‐lymphocyte and cancer cell interaction by single‐cell force spectroscopy [PDF]

, 2010
Sabrina Hoffmann, Guido Wabnitz, Yvonne Samstag, Gerhard Moldenhauer, Thomas Ludwig   +4 more
openalex   +1 more source

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments.
Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo   +9 more
wiley   +1 more source

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. [PDF]

Cells
Tedder B, Bhutani M.
europepmc   +1 more source

In vitro and in vivo properties of a dimeric bispecific single‐chain antibody IgG‐fusion protein for depletion of CCR2⁺ target cells in mice

, 2005
Martin Schneider, Hilke Brühl, Alexandra Wechselberger, Josef Cihak, M. Stangassinger, Detlef Schlöndorff, Matthias Mack   +6 more
openalex   +1 more source

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)₂ antibody [PDF]

, 2010
Frits Aarts, Otto C. Boerman, Robert M. Sharkey, Thijs Hendriks, Chien‐Hsing Chang, William J. McBride, Robert P. Bleichrodt, Wim J.G. Oyen, David M. Goldenberg   +8 more
openalex   +1 more source

Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy. [PDF]

Biomolecules
Lizama-Muñoz A, Plaza-Diaz J.
europepmc   +1 more source

Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells [PDF]

, 2011
Hitoe Torisu‐Itakura, Hans F. Schoellhammer, Myung‐Shin Sim, Reiko F. Irie, Susanne Hausmann, Tobias Raum, Patrick A. Baeuerle, Donald L. Morton   +7 more
openalex   +1 more source

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL. [PDF]

Cancers (Basel)
Kordic A, Phillips TJ, Weiss J.
europepmc   +1 more source

Synthesis and Evaluation of an Anti-MLC1 × Anti-CD90 Bispecific Antibody for Targeting and Retaining Bone-Marrow-Derived Multipotent Stromal Cells in Infarcted Myocardium [PDF]

, 2011
C. William Gundlach, Amy R. Caivano, Maria da Graça Cabreira-Hansen, Amir Gahremanpour, Wells S. Brown, Yi Zheng, Bradley W. McIntyre, James T. Willerson, Richard A. F. Dixon, Emerson C. Perin, Darren G. Woodside   +10 more
openalex   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, Volume 157, Issue 5, Page 954-963, 1 September 2025.
What's new? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source